Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: A single center analysis and review of the literature

References

• Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598
   PubMed Web of Science ®Google Scholar
• Bolwell B J, Kalaycio M, Sobecks R, Andresen S, Kuczkowski E, Bernhard L, et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplantat 2002; 30: 587–591
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817–826
   PubMed Web of Science ®Google Scholar
• Fanning S R, Rybicki L, Kalaycio M, Andresen S, Kuczkowski E, Pohlmann B, et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006; 135: 374–381
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295
   PubMed Web of Science ®Google Scholar
• Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004; 34: 1057–1065
   PubMed Web of Science ®Google Scholar
• Haas P S, Bauchmüller K, Kühnemund A, Finke J, Ihorst G, Engelhardt M. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-center analysis over a 12-year period. Ann Hematol 2006; 85: 191–193
   PubMed Web of Science ®Google Scholar
• Denz U, Haas P, Wäsch R, Einsele H, Engelhardt M. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006; 42: 1591–1600
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Zeiser R, Ihorst G, Finke J, Müller C I. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol 2006; 133: 1–11
   PubMed Web of Science ®Google Scholar
• Müller A MS, Ihorst G, Waller C F, Dölken G, Finke J, Engelhardt M. Intensive chemotherapy with autologous peripheral blood stem cell transplantation during a 10-year period in 64 patients with germ cell tumor. Biol Blood Marrow Transplant 2006; 12: 355–365
   PubMed Web of Science ®Google Scholar
• Arfons L M, Lazarus H M. Total parental nutrition and hematopoietic stem cell ransplantation: an expensive placebo?. Bone Marrow Transplant 2005; 36: 281–288
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M, Glossmann J P, Sienawski M, Sieber M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116–123
   PubMed Web of Science ®Google Scholar
• Wardley A M, Jayson G C, Swindell R, Morgenstern G R, Chang J, Bloor R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110: 292–299
   PubMed Web of Science ®Google Scholar
• Josting A, Sieniawski M, Glossmann J P, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16: 1359–1365
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with Non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151–1158
   PubMed Web of Science ®Google Scholar
• Glossmann J P, Staak J O, Nogova L, Diehl V, Scheid C, Kisro J, et al. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol 2005; 84: 517–525
   PubMed Web of Science ®Google Scholar
• Martin A, Caballero M D, Pérez-Simón J A, López-Holgado N, Mateos M V, Canizo M C, et al. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. Bone Marrow Transplant 2004; 34: 675–682
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Stella-Holowiecka B, Kachel L, et al. Autologous hematopoietic stem cell transplantation for high-risk Hodgkin's disease: a single-center experience with the first 100 patients. Transplantation Proc 2002; 34: 3378–3383
   PubMed Web of Science ®Google Scholar
• Argiris A, Seropian S, Cooper D L. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000; 11: 665–672
   PubMed Web of Science ®Google Scholar
• Mills W, Strang J, Goldstone A H, Linch D C. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma 1995; 17: 263–270
   PubMed Web of Science ®Google Scholar